Cargando…
A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report
BACKGROUND: Primary pulmonary choriocarcinoma (PPC) is a rare malignancy, and only 41 PPC cases have been reported in males up to 2021. Due to its rarity, no standardized treatments for PPC have been established. Cytotoxic chemotherapy has limited efficacy, and the prognosis of advanced PPC is notab...
Autores principales: | Iso, Hirokazu, Hisakane, Kakeru, Terashi, Naoki, Mikami, Erika, Matsuki, Satoru, Sonokawa, Takumi, Atsumi, Kenichiro, Yoshino, Naoyuki, Nagata, Kohji, Seike, Masahiro, Hirose, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493795/ https://www.ncbi.nlm.nih.gov/pubmed/37701113 http://dx.doi.org/10.21037/tcr-23-221 |
Ejemplares similares
-
Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
por: Iso, Hirokazu, et al.
Publicado: (2023) -
Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report
por: Mikami, Erika, et al.
Publicado: (2023) -
Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)